{"id":963849,"date":"2026-05-18T06:48:38","date_gmt":"2026-05-18T10:48:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/"},"modified":"2026-05-18T06:48:38","modified_gmt":"2026-05-18T10:48:38","slug":"context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/","title":{"rendered":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202"},"content":{"rendered":"
\n

\n Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license<\/em>\n <\/p>\n

\n Phase 1 initiation for CT-202 trial expected in third quarter of 2026<\/em>\n <\/p>\n

PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (\u201cContext\u201d or the \u201cCompany\u201d) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (\u201cTCE\u201d) bispecific antibodies for solid tumors, today announced the amendment of the Company\u2019s exclusive license agreement,\u00a0dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company\u2019s Nectin-4 x CD3 T cell engager, in exchange for a $4.5 million upfront payment, and a second and final $2.0 million payment due by August 1, 2026.<\/p>\n

\u201cWe are pleased to announce this amendment which provides us with full economic rights to CT-202 going forward,\u201d said Martin Lehr, Chief Executive Officer of Context. \u201cThis transaction underscores our excitement for CT-202, an increasingly important program within Context\u2019s pipeline, and provides a significant opportunity to capture potential long-term value as we advance CT-202 through development.\u201d<\/p>\n

\n About CT-202<\/strong>
\n
CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment. More information about the CT-202 clinical trial (NCT07545122) can be found on\u00a0https:\/\/clinicaltrials.gov\/<\/a>.<\/p>\n

\n About Context Therapeutics<\/strong>
\n \u00ae<\/sup>
\n
Context Therapeutics Inc. (Nasdaq: CNTX)\u00a0is a clinical-stage biopharmaceutical company advancing T cell engaging (\u201cTCE\u201d) bispecific antibodies for solid tumors. Context\u2019s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com<\/a>\u00a0or follow the Company on\u00a0X<\/a> (formerly\u00a0Twitter)\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Forward-looking Statements<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company\u2019s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201canticipate,\u201d \u201clook forward,\u201d \u201cplan,\u201d \u201cintend,\u201d and similar expressions.<\/p>\n

Forward-looking statements in this press release include, without limitation, statements regarding (i) the Company\u2019s opportunity to capture long-term value as it advances CT-202 through development, (ii) the Company\u2019s expectation that its Phase 1 clinical trial for CT-202 will be initiated in the third quarter of 2026, and (iii) other non-historical statements.<\/p>\n

These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company\u2019s expectations, projections, and estimates of future costs and expenses, capital requirements, the availability of additional financing and the Company\u2019s capital requirements; (ii) the timing, progress, and results of the Company\u2019s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis; (vi) uncertainties related to the regulatory approval process; (vii) the Company\u2019s reliance on third parties; (viii) macroeconomic conditions; and (ix) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements. Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), and in the Company\u2019s other filings with the SEC, including future reports.<\/p>\n

Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, which speak only as of the date of this press release, whether as a result of new information, future events or otherwise.<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (\u201cContext\u201d or the \u201cCompany\u201d) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (\u201cTCE\u201d) bispecific antibodies for solid tumors, today announced the amendment of the Company\u2019s exclusive license agreement,\u00a0dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company\u2019s Nectin-4 x CD3 T cell engager, in exchange for a $4.5 million upfront payment, and a second and final $2.0 million payment due by August 1, … <\/p>\n

Continue reading “Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963849","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (\u201cContext\u201d or the \u201cCompany\u201d) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (\u201cTCE\u201d) bispecific antibodies for solid tumors, today announced the amendment of the Company\u2019s exclusive license agreement,\u00a0dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company\u2019s Nectin-4 x CD3 T cell engager, in exchange for a $4.5 million upfront payment, and a second and final $2.0 million payment due by August 1, … Continue reading "Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T10:48:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202\",\"datePublished\":\"2026-05-18T10:48:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/\",\"name\":\"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=\",\"datePublished\":\"2026-05-18T10:48:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/","og_locale":"en_US","og_type":"article","og_title":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk","og_description":"Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (\u201cContext\u201d or the \u201cCompany\u201d) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (\u201cTCE\u201d) bispecific antibodies for solid tumors, today announced the amendment of the Company\u2019s exclusive license agreement,\u00a0dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company\u2019s Nectin-4 x CD3 T cell engager, in exchange for a $4.5 million upfront payment, and a second and final $2.0 million payment due by August 1, … Continue reading \"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-18T10:48:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202","datePublished":"2026-05-18T10:48:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/","name":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=","datePublished":"2026-05-18T10:48:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc4MCM3NjA2OTk1IzIyMDkxMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963849"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}